ImmunityBio, Inc.IBRX
What ImmunityBio, Inc. does.
This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to:
• our ability to successfully commercialize ANKTIVA globally in NMIBC, NSCLC or other indications or any future approved products in the U.S. or internationally;
• our ability to obtain incremental approvals for ANKTIVA for new indications, including, without limitation, in BCG-unresponsive NMIBC with papillary tumors and NSCLC from the FDA or clearances or approvals from international regulatory agencies for the treatment of patients with NMIBC, NSCLC or other indications;
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $605,000 | $934,000 | $240,000 | $622,000 | $14.7M | $113.3M |
| Net income | -$221.9M | -$346.8M | -$416.6M | -$583.2M | -$413.6M | -$351.4M |
| Free cash flow | -$173.4M | -$308.0M | -$415.7M | -$397.3M | -$398.1M | -$308.8M |
More on IBRX.
- ImmunityBio, Inc. summary
- ImmunityBio, Inc. financial statements
- ImmunityBio, Inc. key metrics
- ImmunityBio, Inc. health scores and style box
- ImmunityBio, Inc. earnings
- ImmunityBio, Inc. dividends
- ImmunityBio, Inc. valuation
- ImmunityBio, Inc. ownership and insiders
- ImmunityBio, Inc. peers
Figures from ImmunityBio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.